Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

162
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
162
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

148
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
148
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.6K
Clinical Trials01:16

Clinical Trials

7.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.0K
Modeling and Similitude01:12

Modeling and Similitude

323
Scaled modeling is a fundamental technique in engineering, enabling the study of large and complex systems by creating smaller, manageable replicas that recreate critical characteristics of the original. In hydrology and civil infrastructure, for example, scaled models of dams help analyze water flow, turbulence, and pressure. This method allows for accurate predictions of real-world behavior within a controlled environment, significantly reducing the cost and time involved in full-scale...
323
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple algebraic expression can determine if a drug's clearance is non-specific or target-mediated.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Genetic characterization of the TAPBP and its allelic association with BF2 in the chicken major histocompatibility complex.

Immunogenetics·2026
Same author

Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure.

Frontiers in artificial intelligence·2026
Same author

Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class I.

Discovery immunology·2026
Same author

Immunopeptidomics-guided identification of functional neoantigens in non-small cell lung cancer.

NPJ precision oncology·2026
Same author

The embryonic origins of site-specific arthritis.

Nature immunology·2026

Related Experiment Video

Updated: Aug 27, 2025

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K

De-risking clinical trial failure through mechanistic simulation.

Liam V Brown1,2, Jonathan Wagg3, Rachel Darley4

  • 1Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK.

Immunotherapy Advances
|September 30, 2022
PubMed
Summary

Mechanistic models combined with clinical trial simulations can predict drug development failures. This approach, applied to a cancer vaccine, identified key limitations and suggested improved trial designs for better efficacy.

Keywords:
late-phase trialmathematical modellingoncologypeptidevaccines

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Related Experiment Videos

Last Updated: Aug 27, 2025

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Area of Science:

  • Pharmacology and Drug Development
  • Immunology
  • Computational Biology

Background:

  • Late-stage clinical trial failures in drug development incur significant financial losses for the pharmaceutical industry.
  • Clinical trial simulation is a crucial strategy for mitigating risks and improving drug development success rates.
  • Integrating mechanistic models with simulations allows for hypothesis testing regarding failure mechanisms and optimization of trial designs.

Purpose of the Study:

  • To demonstrate the utility of combining mechanistic modeling with clinical trial simulations for derisking drug development.
  • To identify specific limitations in a cancer vaccine trial (IMA901) using a T-cell activation model.
  • To propose improved clinical trial designs based on simulation-derived insights.

Main Methods:

  • Development and application of a T-cell activation mechanistic model.
  • Simulation of clinical trials for the IMA901 short-peptide cancer vaccine.
  • Analysis of simulation outputs to identify factors limiting therapeutic response.

Main Results:

  • Simulation results closely matched observed outcomes from the IMA901 clinical trials.
  • Key factors limiting vaccine response were identified as peptide off-rates, competition for dendritic cell (DC) binding, and DC migration times.
  • The model predicted potential improvements in efficacy with alternate trial designs.

Conclusions:

  • Mechanistic models integrated with clinical trial simulations offer a powerful framework for understanding and improving drug development.
  • This approach can complement traditional experimental and data-driven methods.
  • Insights gained can guide the design of more effective clinical trials and highlight potential inter-species differences in drug response.